Wojciech Szczepek

Dr. Wojciech Szczepek


Research Focus & Metrics

Academic Career Length

15Years (2012-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
29 February 2012 in Chemical Communications
Verified
Journal Article
Closed access
PDF file
JFJadwiga Frelek
Jadwiga Frelek
MGMarcin Górecki
Marcin Górecki
MŁMarta Łaszcz
Marta Łaszcz
ASAgata Suszczyńska
Agata Suszczyńska
EVElemér Vass
Elemér Vass
WSWojciech Szczepek
Wojciech Szczepek
For the first time two crystalline forms of the same compound (linezolid polymorphs) were investigated by means of the solid-phase ECD and VCD spectra. The ECD spectra show distinct differences and the band at 221 nm serves as a diagnostic one because it is present in form II but absent in form III. The VCD spectra strongly differ in the diagnostic carbonyl absorption range exhibiting two relatively strong bands of opposite signs.

1 May 2015 in Journal of Pharmaceutical Sciences
Verified
Journal Article
Closed access
PDF file
JFJadwiga Frelek
Jadwiga Frelek
MGMarcin Górecki
Marcin Górecki
ADAlicja Dziedzic
Alicja Dziedzic
EJEwa Jabƚońska
Ewa Jabƚońska
BKBohdan Kamieński
Bohdan Kamieński
WSWojciech Szczepek
Wojciech Szczepek

1 December 2015 in Molecules
Verified
Journal Article
Open access
PDF file
IDIwona Dams
Iwona Dams
AOAnna Ostaszewska
Anna Ostaszewska
MPMaria Puchalska
Maria Puchalska
JCJustyna Chmiel
Justyna Chmiel
PCPiotr Cmoch
Piotr Cmoch
WSWojciech Szczepek
Wojciech Szczepek
During the process development for multigram-scale synthesis of olmesartan medoxomil (OM), two principal regioisomeric process-related impurities were observed along with the final active pharmaceutical ingredient (API). The impurities were identified as N-1- and N-2-(5-methyl-2-oxo-1,3-dioxolen-4-yl)methyl derivatives of OM. Both compounds, of which N-2 isomer of olmesartan dimedoxomil is a novel impurity of OM, were synthesized and fully characterized by differential scanning calorimetry (DSC), infrared spectroscopy (IR), nuclear magnetic resonance spectroscopy (NMR) and high-resolution mass spectrometry/electrospray ionization (HRMS/ESI). Their 1H, 13C and 15N nuclear magnetic resonance signals were fully assigned. The molecular structures of N-triphenylmethylolmesartan ethyl (N-tritylolmesartan ethyl) and N-tritylolmesartan medoxomil, the key intermediates in OM synthesis, were solved and refined using single-crystal X-ray diffraction (SCXRD). The SCXRD study revealed that N-tritylated intermediates of OM exist exclusively as one of the two possible regioisomers. In molecular structures of these regioisomers, the trityl substituent is attached to the N-2 nitrogen atom of the tetrazole ring, and not to the N-1 nitrogen, as has been widely reported up to the present. This finding indicates that the reported structural formula of N-tritylolmesartan ethyl and N-tritylolmesartan medoxomil, as well as their systematic chemical names, must be revised. The careful analysis of literature spectroscopic data for other sartan intermediates and their analogs with 5-(biphenyl-2-yl)tetrazole moiety showed that they also exist exclusively as N-2-trityl regioisomers.